Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New skin booster from human tissue shows promise in wrinkle fight

NCT ID NCT07155278

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested whether a skin booster made from human tissue (phADM) plus hyaluronic acid works better than hyaluronic acid alone for wrinkles and skin texture. Twenty adults received three injections on one cheek with the combination and on the other cheek with HA alone. Researchers measured wrinkle depth, skin density, volume, and lifting over 20 weeks to see which side improved more.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
particulated human acellular dermal matrix (phADM) combined with hyaluronic acid
What this could lead to
If it works, this could offer a more effective option for reducing wrinkles and improving skin firmness and texture.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The improvement over existing treatments may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

20 people

The number who actually took part.

Started

Nov 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged 30 to 65 years old * Those with an Allergan Cheek Smoothness Scale (ACSS) score of 2-3 during screening Exclusion Criteria: * Those who have received dermal fillers, botulinum toxin injections, mesotherapy, or other cosmetic procedures (e.g., laser) on the face within 12 months of screening or plan to receive such treatments during the trial period. * Those who received facial wrinkle correction treatment within 6 months of screening * Those with inflammatory diseases in the facial area * Those with infectious diseases, skin grafts, keloids, or hypertrophic scars on the face. * Those with autoimmune diseases * Those who have experienced anaphylaxis or severe complex allergies for any reason * Those who were prescribed anticoagulant therapy within 2 weeks of the screening date * Those with a history of serious cardiopulmonary disease * Breastfeeding * Those who have started using or taking external or oral agents for wrinkle improvement within 30 days of screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Photoaged facial skin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Severance Hospital, Yonsei University College of Medicine

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.